The BioPharm Brief: CAR-T Advances, Pediatric Biologic Approval, and Oral GLP-1 Progress

Today on The BioPharm Brief, we’re looking at three developments across oncology, immunology, and metabolic disease that highlight how innovation is expanding into harder-to-treat populations—and increasingly, into younger patients.

First, in oncology, A2 Biotherapeutics is set to present early data at ASCO 2026 on its A2B694 CAR-T therapy targeting HLA-A*02 loss of heterozygosity in solid tumors. This approach is designed to improve tumor specificity by distinguishing between healthy and cancerous cells based on genetic differences. While CAR-T therapies have seen success in hematologic cancers, solid tumors have remained a major challenge. Early signals from this program could offer insight into whether more precise targeting strategies can help overcome those limitations.

In immunology, the FDA has approved dupilumab for children aged 2 to 11 years with chronic spontaneous urticaria who remain symptomatic despite antihistamine treatment. This marks the first biologic option for younger patients with this condition, which is driven in part by type 2 inflammation. The approval is backed by Phase 3 data showing reductions in itch severity and overall disease activity, expanding treatment options for a population with limited alternatives.

And in metabolic disease, oral semaglutide is showing promise in adolescents with type 2 diabetes. Results from the Phase 3 PIONEER TEENS trial demonstrated a statistically significant reduction in HbA1c compared to placebo. If approved, it could become the first oral GLP-1 therapy for this age group, offering a non-injectable option in a space where treatment choices remain constrained.

Across all three stories, a clear trend is emerging: targeted therapies are moving earlier in disease and into populations that have historically lacked effective options.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

KEY TAKEAWAYS

• Precision approaches like CAR-T are expanding into solid tumors with new targeting strategies
• Dupilumab approval introduces the first biologic for young children with chronic spontaneous urticaria
• Oral semaglutide could become a first-in-class oral GLP-1 option for adolescents with type 2 diabetes